Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
Abstract Background Mantle cell lymphoma (MCL) is an aggressive B-non-Hodgkin lymphoma with generally poor outcome. MCL is characterized by an aberrantly high cyclin D1-driven CDK4 activity. New molecular targeted therapies such as inhibitors of the ubiquitin-proteasome system (UPS) have shown promi...
Main Authors: | Simon Heine, Markus Kleih, Neus Giménez, Kathrin Böpple, German Ott, Dolors Colomer, Walter E. Aulitzky, Heiko van der Kuip, Elisabeth Silkenstedt |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-09-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0657-6 |
Similar Items
-
The Effect of Noxa Serine-13 Phosphorylation on Hyperthermia-Induced Apoptosis
by: Morey, Trevor
Published: (2012) -
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms
by: Tri Nguyen, et al.
Published: (2018-11-01) -
Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
by: Jin J, et al.
Published: (2018-07-01) -
ABT-737 synergizes with Bortezomib to kill melanoma cells
by: Steven N. Reuland, et al.
Published: (2012-02-01) -
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation
by: Robert W. Chen, et al.
Published: (2018-06-01)